Economic Burden of Lyme Disease: Billions in Costs and Rising
STILL SICK AFTER TREATMENT?
REPEATED VISITS AND TESTS?
THE COST OF LYME DISEASE ADDS UP QUICKLY
The economic burden of Lyme disease is substantial, reaching billions of dollars annually in the United States.
An estimated 240,000 to 440,000 individuals are diagnosed each year, with average treatment costs of approximately $3,000 per patient annually.
When persistent symptoms and ongoing care are included, total healthcare costs may reach $1.3 billion per year.
“Our study looks at the actual costs of treating patients in the year following their Lyme diagnosis,” explains Emily Adrion, MS. These costs include repeated medical visits and testing for unresolved symptoms.
What Drives the Cost?
Much of the economic burden stems from patients who continue to experience symptoms after treatment.
Common persistent symptoms include:
- Fatigue
- Muscle and joint pain
- Cognitive impairment
These symptoms often require additional evaluations, testing, and follow-up care.
Even after diagnosis, care does not end—and costs continue to accumulate.
Persistent Symptoms Are Common
Research suggests that persistent symptoms may be more common than previously reported.
- 63% of treated patients had at least one PTLDS-related diagnosis
- This is significantly higher than individuals without Lyme disease
In contrast, CDC estimates suggest that only 10–20% of patients experience lingering symptoms.
This gap raises questions about whether the true burden is being underestimated.
Increased Healthcare Utilization
Patients with Lyme disease use significantly more healthcare resources:
- 5.5 times more likely to be diagnosed with fatigue-related conditions
- 87% more physician visits within one year
- 71% more emergency room visits compared with matched controls
These increases reflect the complexity of managing persistent symptoms.
The True Cost May Be Higher
Earlier estimates suggest Lyme disease may be even more costly than current figures indicate.
- Average annual cost per patient estimated at $16,199
- Total national cost estimated at $203 million based on reported cases
However, since actual case numbers may be much higher than reported, the total economic burden may approach $2 billion annually.
Much of this cost is indirect—lost productivity, disability, and nonmedical expenses.
Comparison With Other Chronic Conditions
The economic burden of Lyme disease may exceed that of several other chronic illnesses:
- $10,911 for fibromyalgia
- $10,716 for rheumatoid arthritis
- $13,094 for lupus
This highlights the significant and often underrecognized impact of Lyme disease.
Why This Matters
Much of the ongoing cost reflects uncertainty in diagnosis and treatment.
Patients often undergo repeated testing, consultations, and retreatment due to persistent symptoms.
“Many people are going back to the doctor with persistent symptoms, undergoing multiple tests, and being retreated.”
Debate continues over how to define and treat these patients, whether described as PTLDS or chronic Lyme disease.
Regardless of terminology, the economic and clinical burden is clear.
Clinical Perspective
Lyme disease is not only a clinical challenge—it is also a public health and economic issue.
Improving early diagnosis, refining treatment strategies, and addressing persistent symptoms are essential to reducing both patient suffering and societal costs.
Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.
Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention
